Prestige Consumer Healthcare Inc (PBH)

Over the past six months, Prestige Consumer Healthcare's stock (PBH) has experienced a share price decline of 31.12% between March 31, 2025, and March 27, 2026. In early April 2026, the stock faced pressure due to regulatory scrutiny. On March 20, 2026, the company announced an agreement to acquire the Breathe Right brand and other brands from Foundation Consumer Healthcare for $1.045 billion. Prestige Consumer Healthcare reported its Q3 fiscal 2026 results, with revenue of $283.4 million and adjusted diluted EPS of $1.14, and closed the acquisition of Pillar5 Pharma. The company revised its fiscal 2026 outlook, lowering revenue and adjusted EPS guidance primarily due to supply constraints for Clear Eyes. Q2 and Q1 fiscal 2026 revenues decreased year-over-year, mainly due to limited ability to supply demand for Clear Eyes.

Demand for some of Prestige Consumer Healthcare's products exhibits seasonality, particularly in the allergy and cold relief category, suggesting that sales for certain product lines may fluctuate throughout the year based on seasonal illness patterns.

Prestige Consumer Healthcare, Inc. (PBH) is an American company specializing in over-the-counter (OTC) health and personal care products. It operates within the Healthcare sector, primarily in the Pharmaceuticals and Personal Products industries, and is recognized as one of the largest pure-play OTC healthcare providers. The company offers a diverse portfolio of leading brands in niche consumer health categories, including Women's Health, Eye Care, Pain Relief, Motion Sickness, Wart Removal, Lice Treatment, Digestive Health, Pediatric Needs, Sleep Aids, and other notable brands.

Prestige Consumer Healthcare's primary market is North America, generating approximately 85% of its total revenue. The company also has a significant international presence in Australia, New Zealand, certain Asian markets, and select European countries.

In the past year, Prestige Consumer Healthcare has focused on enhancing brand equity through marketing and brand-building initiatives for products like Hydralyte and Summer's Eve. The company faced challenges related to its Clear Eyes brand due to supply constraints, which impacted revenue. The company has indicated that the "Clear Eyes issue gradually recovers."

Institutional investors represent the largest segment of Prestige Consumer Healthcare's ownership, holding approximately 84.8% to 99.95% of the company's stock. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., and State Street Global Advisors, Inc. Insider ownership is relatively small, ranging from approximately 0.8% to 1.40% of the stock.